ALX Oncology Q3 net loss $24.6M; cash $385M; acquired ScalmiBio

ALX ONCOLOGY HOLDINGS INC

2022-Q3 EPS reported -$1.37

GAAP net loss $24.6M ($0.61/sh) vs $10.8M ($0.36/sh) in Q3 2020; non-GAAP loss $20.4M.
R&D expenses $18.2M, up from $5.3M, driven by higher clinical costs and stock-based comp.
Cash and equivalents $385.1M; runway projected through 2024.
Acquired ScalmiBio Oct 2021 for ~$4.5M upfront + $2M milestone and royalties; gains SHIELD ADC platform.
Dosed first patients in ASPEN-05 (AML) and Zymeworks combo trial; ASH/SITC data presented or pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.